GlassScriptPhysician profile
Saroj Misra
NPI 1336130970
$43,701.16
in general payments reported to CMS, 2019-2025
13 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2021: $121 · 2022: $594 · 2023: $10K · 2024: $16K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $31K · Consulting Fee: $8,873 · Food and Beverage: $1,461 · Travel and Lodging: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $31,000.00 |
| Consulting Fee | $8,872.50 |
| Food and Beverage | $1,461.15 |
| Travel and Lodging | $1,154.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $31,950.39 | 2019-2025 | Immunocap |
| E.R. Squibb & Sons, L.L.C. | $10,327.36 | 2025 | |
| Novo Nordisk INC | $353.17 | 2024-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $243.93 | 2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $189.26 | 2019 | |
| Allergan, INC. | $141.48 | 2019 | |
| Glaxosmithkline, LLC. | $121.36 | 2021 | |
| Impel Pharmaceuticals INC. | $107.10 | 2023 | Trudhesa |
| Abbott Laboratories | $104.36 | 2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $93.24 | 2019 | |
| Exact Sciences Corporation | $37.59 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $19.68 | 2024 | |
| Merck Sharp & Dohme LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saroj Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.